Viatris completes acquisition of Pacira BioSciences
Viatris has completed its acquisition of Pacira BioSciences, bringing the US non opioid pain management business into its innovative medicines division. Viatris offered $36.50 per share in cash, with approximately 66% of Pacira shares tendered before completion. HPC could identify specialist pharmaceutical businesses, medical technology suppliers and healthcare companies seeking strategic buyers.
If you are interested to enquire further, please fill in the form below with your details and one of our consultants will contact you shortly.
Get in Touch
We’ll get back to you shortly.